Trials / Completed
CompletedNCT00483730
Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)
A Multi-centre, Double-blind, Placebo-controlled, Randomised, Parallel Group Clinical Trial to Evaluate Efficacy and Safety of Actovegin® in Diabetic Type 2 Patients With Symptomatic Diabetic Peripheral Polyneuropathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 569 (actual)
- Sponsor
- Nycomed · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To assess clinical efficacy and safety of Actovegin in type 2 diabetic patients with symptomatic diabetic peripheral polyneuropathy after 250 ml i.v. infusions once daily for 20 days followed by oral treatment 600 mg × 3 daily for 140 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deproteinised hemoderivative of calf blood (Actovegin) | Symptomatic diabetic peripheral polyneuropathy |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2008-05-01
- Completion
- 2008-12-01
- First posted
- 2007-06-07
- Last updated
- 2012-05-07
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00483730. Inclusion in this directory is not an endorsement.